13 September 2016 in Scientific Reports
Accumulating evidence implies that both AKT1 and GABAA receptor (GABAAR) subunit genes are involved in schizophrenia pathogenesis. Activated Akt promotes GABAergic neuron differentiation and increases GABAAR expression on the plasma membrane. To elucidate the role of Akt1 in modulating GABAergic functions and schizophrenia-related cognitive deficits, a set of 6 in vitro and in vivo experiments was conducted. First, an Akt1/2 inhibitor was applied to evaluate its effect on GABAergic neuron-like cell formation from P19 cells. Inhibiting Akt resulted in a reduction in parvalbumin-positive neuron-like cells. In Akt1−/− and wild-type mice, seizures induced using pentylenetetrazol (a GABAAR antagonist) were measured, and GABAAR expression and GABAergic interneuron abundance in the brain were examined. Female Akt1−/− mice, but not male Akt1−/− mice, exhibited less pentylenetetrazol-induced convulsive activity than their corresponding wild-type controls. Reduced parvalbumin-positive interneuron abundance and GABAAR subunit expression, especially in the hippocampus, were also observed in female Akt1−/− mice compared to female wild-type mice. Neuromorphometric analyses revealed significantly reduced neurite complexity in hippocampal pyramidal neurons. Additionally, female Akt1−/− mice displayed increased hippocampal oscillation power and impaired spatial memory compared to female wild-type mice. Our findings suggest that Akt1 deficiency modulates GABAergic interneurons and GABAAR expression, contributing to hippocampus-dependent cognitive functional impairment.
1 January 1995 in Environment International
6 October 2025 in Translational Psychiatry
Schizophrenia, a debilitating disorder with genetic and neurobiological underpinnings, often manifests cognitive deficits, including impaired decision-making. Utilizing Akt1 heterozygous mutant (HET) mice as a model, which mimic schizophrenia due to AKT1’s implication as a susceptibility gene, we investigated the involvement of Akt1 and its neural mechanisms influencing strategic decision-making to identify potential therapeutic targets for schizophrenia-associated cognitive impairments. In six experiments, we first revealed that lesions targeting the dorsomedial striatum (DMS) significantly impacted performance in a mouse version of the two-choice probabilistic decision-making task, surpassing effects observed in other striatal subregions. Behavioral assessments in HET mice unveiled notable disturbances, including reduced accumulated trials to reach criteria, diminished ratio of lose-stay behavior, elevated learning rates, and decreased choice consistency in reinforcement learning models. Moreover, we found a strong correlation between DMS local field potential power and choice outcome, particularly evident in no-reward condition. The behavioral abnormalities observed in HET mice were restored when the DMS was chemogenetically inhibited, while their locomotor activity remained unaffected. Furthermore, RNA-seq analysis and immunohistochemistry uncovered a decrease in the number of striatal parvalbumin (PV) interneurons in HET mice. Targeted lesioning of PV interneurons in the DMS of wild-type mice resulted in behavioral alterations mirroring those in HET mice. In summary, our findings suggest that Akt1 deficiency-induced downregulation of PV expression alters neural oscillations in the DMS, influencing choice strategies, especially in no-reward condition during probabilistic decision-making. These results underscore the crucial involvement of AKT1 and PV interneurons in modulating strategic decision-making, with particular relevance to the understanding of schizophrenia.
1 January 2016 in Journal of Medical Sciences
Background: Atypical meningiomas fall into a category World Health Organization Grade II, which have higher local recurrence rates and lower survival rates than their benign counterparts. The aim of this study is to review the outcome of newly diagnosed patients with atypical meningioma after therapy. Methods: We conducted a retrospective review of the medical records of patients having atypical meningiomas who were treated in our hospital between January 2005 and December 2014. Their age, sex, initial presentation, tumor location, tumor size, extent of resection, tumor recurrence or tumor progression, duration of follow-up, adjuvant therapy, and outcome were reviewed. Results: There were 27 consecutive patients (15 male and 12 female) having fresh intracranial atypical meningiomas treated in our hospital between January 2005 and December 2014. Their mean age at diagnosis was 60.81 years. Twenty-three patients (85.19%) underwent total resection of the tumor, whereas 4 patients (14.81%) had partial resection of their tumors during their first time of surgery. Fifteen patients (55.56%) had finished adjuvant radiotherapy. Nine patients (33.33%) had tumor progression or recurrence during follow-up, and 4 of them were proved to have malignant transformation to anaplastic meningiomas in the following operations. The mean time to tumor progression or recurrence of these nine patients was 17.67 months. Nineteen patients (70.37%) had a favorable outcome, 7 patients (25.93%) had an unfavorable outcome, and we lost 1 patient (3.7%) due to disease progression. Conclusions: Surgery remains the standard treatment to atypical meningioma, and postoperative adjuvant radiotherapy is still controversial especially to those who undergo total surgical resection of the tumors. Our study reveals that early postoperative adjuvant radiotherapy seems to play a role in local control. Atypical meningioma can have malignant transformation to anaplastic meningioma, so aggressive treatment and follow-up are essential to manage this particular tumor.
11 June 2026 in Translational Psychiatry
Neuropsychiatric disorders such as schizophrenia frequently exhibit marked sex differences in onset, clinical features, and treatment response. However, the molecular and developmental bases of these differences remain poorly defined. Here, we report a sex-dependent effect of developmental, paralog-selective GSK3B inhibition on working memory (WM) in the Df(16)A
+/−
mouse model of 22q11.2 deletion syndrome (22q11.2DS), a genetic condition conferring high risk for schizophrenia. Pharmacological inhibition of GSK3B with BRD3731 rescued WM deficits and enhanced prefrontal cortex (PFC)–ventral hippocampus (vHPC) theta synchrony in male Df(16)A
+/−
mice, but had no benefit in female mutants and impaired performance in wild-type (WT) females. Transcriptomic profiling of the postnatal PFC revealed previously unrecognized sex-by-genotype interactions in gene expression associated with the 22q11.2 deletion also implicating GSK3B-associated pathways. Notably, Gsk3b expression itself displayed opposing patterns in Df(16)A
+/−
mice relative to WT mice, being elevated in males and reduced in females, potentially explaining the observed sex-specific behavioral and circuit responses. Our findings suggest that GSK3B is part of a broader, sexually dimorphic gene network that governs PFC circuit maturation and cognitive function. Specifically, our transcriptomic profiling delineates a postnatal window where the 22q11.2DS model exhibits these sexually dimorphic signatures. Notably, these signatures include many genes previously implicated in schizophrenia, autism, and intellectual disability, likely shaping the disorder’s sex-specific pathophysiology. More broadly, this work underscores the importance of incorporating sex as a biological variable in translational research and supports precision psychiatry approaches that align interventions with sex-specific neurobiological profiles.
28 April 2022 in Biological Psychiatry